Our Philadelphia Byetta drug injury lawyers are evaluating cases involving people who have developed pancreatic cancer and other serious injuries from the type-2 diabetes drug Byetta. Byetta (exenatide) is a twice-daily injectable medication categorized as a glucagonlike peptide 1 (GLP-1) receptor agonist, or incretin mimetic.
Byetta, manufactured by Eli Lilly and Company, Amylin Pharmaceuticals, Bristol-Myers Squibb, and AstraZeneca, has been associated with serious injuries, including:
- hemorrhagic pancreatitis
- necrotizing pancreatitis
- pancreatic cancer
- thyroid cancer
- altered kidney function
- renal insufficiency
- kidney failure
- wrongful death
Byetta and Pancreatic Cancer
Byetta acts on a patient’s GLP-1 receptor activity to lower blood sugar levels after eating. As an incretin mimetic, it mimics natural incretin hormones, which stimulate the pancreas, in non-diabetics, to release insulin in response to a meal. While Byetta enables type-2 diabetics whose pancreases cannot produce sufficient natural incretins to reduce excess blood sugar following a meal, it may also increase the patient’s risk of pancreatic cancer.
Additional incretin mimetics and incretin therapy drugs include:
- Onglyza (see Philadelphia Onglyza Drug Injury Lawyers)
- Januvia (see Philadelphia Januvia Drug Injury Lawyers)
- Janumet (see Philadelphia Janumet Drug Injury Lawyers)
- Victoza (see Philadelphia Victoza Drug Injury Lawyers)
- Bydureon (see Philadelphia Bydureon Drug Injury Lawyers)
- Janumet XR
Byetta Warnings and Studies
A study reported in the May 1, 2010, issue of Annals of Pharmacotherapy found an association between Byetta and other GLP-1 agonist usage and acute pancreatitis.
A study reported in the July 2011 issue of Gastroenterology revealed that users of Byetta (exenatide) had 6 times the risk of pancreatitis than non-users. Byetta users also showed an increased risk of pancreatic cancer. The study included the GLP-1 receptor agonist Byetta and the dipeptidyl peptidase-4 (DPP-4) inhibitor Januvia (sitagliptin). Study authors stated that the results “raised caution about the potential long-term actions of [Byetta] to promote pancreatic cancer.”
The U.S. Food and Drug Administration (FDA) published a March 14, 2013 drug safety communication warning of the potential increased risk of pancreatitis and pancreatic duct metaplasia with Byetta and other incretin mimetics / incretin therapies.
A study reported on April 8, 2013 by the National Institutes of Health (NIH) revealed a significant increase in the risk of acute pancreatitis in Byetta (exenatide) and Januvia (sitagliptin) users. Individuals studied had pancreases 40% larger than normal size.
Lawsuits filed by Philadelphia Byetta drug injury lawyers may allege that Byetta manufacturers Eli Lilly and Company, Amylin Pharmaceuticals, Bristol-Myers Squibb, and AstraZeneca:
- manufactured and marketed a defective drug with unreasonably dangerous side effects
- performed insufficient pre-market tests to identify serious Byetta side effects
- provided insufficient warnings to doctors and consumers about serious potential Byetta side effects, including pancreatic cancer
- falsely and aggressively advertised Byetta with knowledge of serious side effect risks, including pancreatic cancer
Contact our Philadelphia Byetta Drug Injury Lawyers
If you or a family member developed pancreatic cancer or another serious injury following use of the type-2 diabetes drug Byetta, you may be entitled to compensation from the manufacturers. Contact our Philadelphia Byetta drug injury lawyers, today, to inquire about filing a Byetta lawsuit.